Daniel Peterson

Daniel Peterson, MD, is a doctor in Nevada specialising in ME/CFS. He helped establish the Whittemore Peterson Institute (WPI) which was renamed in 2016 to the Nevada Center for Biomedical Research. He left in 2010 to return to private practice. Dr. Peterson was at the epicenter of the 1984 Incline Village chronic fatigue syndrome outbreak.

He is one of the authors of the 2003 Canadian Consensus Criteria for Myalgic Encephalomyelitis, published as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome:Clinical Working Case Definition, Diagnostic and Treatment Protocols

Dr. Peterson was the first physician to use Ampligen in the treatment for ME/CFS, using it on Nancy Kaiser, a very severe patient. He has participated in every Ampligen trial since, up to the AMP-511, open label, cost-recovery trial available today.

Awards

 * 2003, Rudy Perpich Senior Lectureship Award, presented to a distinguished CFS/FM scientist, physician or healthcare worker awarded by IACFS/ME
 * 2007, Nelson Gantz Outstanding Clinician Award awarded to a physician who emulates Nelson Gantz's clinical acumen, his passion for medicine, and his empathy for persons with CFS/FM awarded by IACFS/ME

Studies

 * 2015, Findings from a clinical and laboratory database developed for discovery of pathogenic mechanisms in myalgic encephalomyelitis/chronic fatigue syndrome. Abstract
 * 2015, Chronic fatigue syndrome and co-morbid and consequent conditions: evidence from a multi-site clinical epidemiology study. Abstract
 * 2012, A double-blind, placebo-controlled, randomized, clinical trial of the TLR-3 agonist rintatolimod in severe cases of chronic fatigue syndrome."Abstract: 'A Phase III prospective, double-blind, randomized, placebo-controlled trial comparing twice weekly IV rintatolimod versus placebo was conducted in 234 subjects with long-standing, debilitating CFS/ME at 12 sites. The primary endpoint was the intra-patient change from baseline at Week 40 in exercise tolerance (ET). Secondary endpoints included concomitant drug usage, the Karnofsky Performance Score (KPS), Activities of Daily Living (ADL), and Vitality Score (SF 36). Subjects receiving rintatolimod for 40 weeks improved intra-patient placebo-adjusted ET 21.3% (p = 0.047) from baseline in an intention-to-treat analysis. Correction for subjects with reduced dosing compliance increased placebo-adjusted ET improvement to 28% (p = 0.022). The improvement observed represents approximately twice the minimum considered medically significant by regulatory agencies. The rintatolimod cohort vs. placebo also reduced dependence on drugs commonly used by patients in an attempt to alleviate the symptoms of CFS/ME (p = 0.048). Placebo subjects crossed-over to receive rintatolimod demonstrated an intra-patient improvement in ET performance at 24 weeks of 39% (p = 0.04). Rintatolimod at 400 mg twice weekly was generally well-tolerated."

ME/CFS Alert

 * 2013, Episode 50, ME/CFS Alert interview
 * 2012, Episode 26, ME/CFS Alert interview

Invest in ME International ME Conference

 * 2013, Speaker at the 8th Invest in ME International ME Conference on Key Note Speech: The Mainstreaming of ME Research DVD available
 * 2012, Speaker at the 7th Invest in ME International ME Conference on Clinical Research Update 2012 DVD available
 * 2009, Speaker at the 4th Invest in ME International ME Conference on Treatment Regimes for the Most Severe Cases DVD available
 * 2007, Speaker at the 2nd Invest in ME International ME Conference on Biomedical Research DVD available

Other

 * 2015, 2015 De osynliga -Seminarium om ME/CFS, Sweden 19 October
 * 2012, Phoenix Rising - Dr Daniel Peterson (July 12)
 * 2011, Dr. med. Dan Peterson (Simmaron Research) - Diagnose und Behandlung von ME/CFS, Teil 2
 * 2011, Dr. med. Dan Peterson (Simmaron Research) - Diagnose und Behandlung von ME/CFS, Teil 1
 * 2000 Documentary, I Remember Me, directed by Kim A. Snyder
 * 1996, Primetime Live TV Show - Sick and Tired

Online presence

 * Profile
 * PubMed

Learn more

 * Wikipedia - Daniel Peterson (physician)
 * 1990, Chronic Fatigue Syndrome